TScan Therapeutics's total assets for Q2 2025 were $298.56M, a decrease of -10.26% from the previous quarter. TCRX total liabilities were $121.85M for the fiscal quarter, a -0.54% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.